Lanraplenib

DB14770InvestigationalSmall molecule

Lanraplenib is under investigation in clinical trial NCT03285711 (Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)).

Mechanism: Pharmacologically active on Tyrosine-protein kinase SYK
Curator reviewed
Formula / weight: C₂₃H₂₅N₉O · 443.515 g/mol (avg)

Resolves to

Compound

UNIIA6U64OU57ECAS1800046-95-0ChEMBLCHEMBL3986824

Structure

InChIKeyXCIGZBVOUQVIPI-UHFFFAOYSA-NSMILESNC1=CN=CC(=N1)C1=CN2C=CN=C2C(NC2=CC=C(C=C2)N2CCN(CC2)C2COC2)=N1

Targets

P43405SYK

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lanraplenib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account